Geron (GERN) shares +7.8% to $2.59 after Stifel Nicolas initiates the biotech company with a...

|About: Geron Corporation (GERN)|By:, SA News Editor

Geron (GERN) shares +7.8% to $2.59 after Stifel Nicolas initiates the biotech company with a "buy" rating and gives it a price target of $4. The rating adds to the positive buzz surrounding Geron - a Seeking Alpha article earlier this month said the firm's drugs "have the potential to change the way cancer is treated."